Medicaid Pharmacy and Therapeutics Committee Agenda for December 8, 2006

The Pharmacy & Therapeutics Committee will meet December 8, 2006, from 9:00 a.m. to 3:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

Agenda Items:

1. Identification of preferred drugs in the therapeutic class of Ophthalmic Quinolones

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Ciloxan solution/ointment (ciprofloxacin), ciprofloxacin, Ocuflox (ofloxacin), ofloxacin, Quixin (levofloxacin), Vigamox (moxifloxacin), Zymar (gatifloxacin)

2. Identification of preferred drugs in the therapeutic class of Otic Quinolones

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Cipro HC (ciprofloxacin/hydrocortisone), Ciprodex (ciprofloxacin/dexamethasone), Floxin (ofloxacin)

3. Identification of preferred drugs in the therapeutic class of Ophthalmic Antihistamines

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Elestat (epinastine), Emadine (emedastine), ketotifen, Optivar (azelastine), Patanol (olopatadine), Zaditor (ketotifen)

4. Identification of preferred drugs in the therapeutic class of Immunomodulators (Injectable)

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drug(s) Affected: Enbrel (etanercept), Humira (adalimumab), Kineret (anakinra)

5. Review of the Cholesterol Absorption Inhibitors (CAIs) therapeutic class

  • Description: The Committee will review the CAI therapeutic class to determine whether the class should be included in the Preferred Drug Program.

    Drug Affected: Zetia (ezetimibe)
TimeAgenda
9:00 - 9:15Welcome and Introductions
9:15 - 10:15Comments from interested parties*
10:15 - 10:45Clinical Review of Ophthalmic Quinolones
10:45 - 11:15Clinical Review of Otic Quinolones
11:15 - 11:45Clinical Review of Ophthalmic Antihistamines
11:45 - 12:45Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information)
12:45 - 1:00Final Recommendations for preferred drugs (Quinolones, Antihistamines)
1:00 - 1:30 Clinical Review of Immunomodulators (Injectable)
1:30 - 2:00 Review of the Cholesterol Absorption Inhibitor (CAI) Class
2:00 - 2:30 Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information)
2:30 - 2:45 Final Recommendations for preferred drugs (Immunomodulators, CAIs)
2:45 - 3:00 DOH Update, Final Comments and Adjournment

*Interested parties must notify DOH at least 72 hours in advance of their request to speak at the committee meeting. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&TCommittee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit a clinical study or a clinical report, rather than comments, must submit the study at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material. If such material is submitted after this time, it cannot be considered by the Committee.

Posted November 8, 2006